Evidence map›Paper›PMID 31065878›Full record

ArticleGastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association2019

Conversion gastrectomy for stage IV unresectable gastric cancer: a GIRCG retrospective cohort study.

Leonardo Solaini, Silvia Ministrini, Maria Bencivenga, Alessia D'Ignazio, Elisabetta Marino, Chiara Cipollari, Beatrice Molteni, Gianni Mura, Daniele Marrelli, Luigina Graziosi and 4 more

Abstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers.

0numbers the graph read from it
0cells of the map it votes in
44citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

44 citing papers in PubMed.

  1. Trial
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Intratumoral CXCL13Journal for immunotherapy of cancer · 2024
    Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Leonardo SolainiGeneral and Oncologic Surgery, Department of Surgery, Morgagni-Pierantoni Hospital, Via Forlanini 34, Forlì, Italy.ORCID 0000-0002-5031-9285
Silvia MinistriniDepartment of Experimental and Clinical Sciences, University of Brescia, Brescia, Italy.
Maria BencivengaGeneral and Upper GI Surgery Division, University of Verona, Verona, Italy.
Alessia D'IgnazioDepartment of Surgery, Policlinico le Scotte- University of Siena, Siena, Italy.
Elisabetta MarinoDepartment of Surgery, Santa Maria della Misericordia Hospital University of Perugia, Perugia, Italy.
Chiara CipollariGeneral and Upper GI Surgery Division, University of Verona, Verona, Italy.
Beatrice MolteniDepartment of Experimental and Clinical Sciences, University of Brescia, Brescia, Italy.
Gianni MuraDepartment of Surgery, Azienda USl Toscana SudEst- Arezzo, Arezzo, Italy.
Daniele MarrelliDepartment of Surgery, Policlinico le Scotte- University of Siena, Siena, Italy.
Luigina GraziosiDepartment of Surgery, Santa Maria della Misericordia Hospital University of Perugia, Perugia, Italy.
Franco RovielloDepartment of Surgery, Policlinico le Scotte- University of Siena, Siena, Italy.
Giovanni De ManzoniGeneral and Upper GI Surgery Division, University of Verona, Verona, Italy.
Guido A M TiberioDepartment of Experimental and Clinical Sciences, University of Brescia, Brescia, Italy.
Paolo MorgagniGeneral and Oncologic Surgery, Department of Surgery, Morgagni-Pierantoni Hospital, Via Forlanini 34, Forlì, Italy. morgagni2002@libero.it.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe aim of this study is to report the experience with conversion surgery from six Gruppo Italiano Ricerca Cancro Gastrico (GIRCG) centers, focusing our analysis on factors affecting survival and the risk of recurrence.

methodsA retrospective, multicenter cohort study was performed in patients who had undergone conversion gastrectomy between 2005 and 2017. Data were extracted from a GIRCG database including all metastatic gastric cancer patients submitted to surgery. Only stage IV unresectable tumors/metastases which became resectable after chemotherapy were included in this analysis.

resultsForty-five resected M1 patients were included in the analysis. Reasons for being deemed unresectable at diagnosis were peritoneal involvement (PCI > 6) (n = 38, 84.4%), distant metastatic nodes (n = 3, 6.6%) and extensive liver involvement (n = 4, 8.8%). Median follow-up was 25 months (IQR 9-50). Median overall survival from surgery was 15 months and 1-, 3- and 5-year survivals were 57.2, 36.1 and 24%, respectively. Median progression-free survival was 12 months with 1- and 3-year survival of 46.4 and 33.9%, respectively. At cox regression analysis the only independent prognostic factor for OS was the presence of more than one type of metastasis (HR 4.41, 95% CI 1.72-11.3, p = 0.002). A positive microscopic resection margin was the only risk factor for recurrence (HR 5.72, 95% CI 1.04-31.4, p = 0.045).

conclusionsUnresectable stage IV GC patients could benefit from radical surgery after chemotherapy and achieve long survivals. The main prognostic factor for these patients was the presence of more than one type of extra-gastric metastatic involvement.

Indexed as

Antineoplastic AgentsCohort StudiesCombined Modality TherapyFemaleFollow-Up StudiesGastrectomyHumansMaleMiddle AgedNeoplasm MetastasisNeoplasm StagingPrognosisProgression-Free SurvivalRetrospective StudiesRisk FactorsStomach NeoplasmsAntineoplastic AgentsConversion surgeryGastrectomyMetastasesPalliative chemotherapyStage IV gastric cancerSurvival

Identifiers

PMID31065878

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.